varespladib methyl ester
Small moleculeexperimental
A-001 was the second abort test of the Apollo spacecraft. — Wikipedia
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00434473)
Timeline
Indications
Studied for
- Acute Chest Syndrome · Phase 2
- Acute Coronary Syndrome · Phase 3
- Anemia, Sickle Cell · Phase 2
- Arterial Occlusive Diseases · Phase 2
- Coronary Artery Disease · Phase 2
- COVID-19 · Phase 2
- Healthy Volunteers · Phase 1
- Kidney Failure, Chronic · Phase 1
- Severe Acute Respiratory Syndrome · Phase 2
- Snake Bites · Phase 2
- Venoms · Phase 2
Mechanism of action
- Phospholipase A2 group IIAINHIBITOR
PLA2G2A inhibitor
Inhibits sPLA2 activity with an IC50=9 +/- 1 nM
- Group X secretory phospholipase A2INHIBITOR
PLA2G10 inhibitor
- Phospholipase A2 group VINHIBITOR
PLA2G5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1- Mol. weight
- 380.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaA-001 ↗
- ChEMBLCHEMBL2105659 ↗
- ChEMBLCHEMBL148674 ↗
Also known as
- ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate
- a-001
- a-001
- a-002
- a-002
- a-002
- a-002
- ly315920
- ly 315920
- ly-315920
- ly-315920
- ly-315920
- ly333013
- ly-333013
- ly-333013
- s-3013
- s-3013
- s 5920
- s-5920
- varepladib
- varepladib
- varespladib
- varespladib
- varespladib
- varespladib
- varespladib
- varespladib methyl
- varespladib methyl
- varespladib methyl
- varespladib methyl
- varespladib methyl
- varespladib methyl ester
- varespladib methyl ester
- varespladib sodium
- varespladib sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05717062 | Phase 2 | May 30, 2023 | Ophirex, Inc. |
| NCT04996264 | Phase 2 | Aug 15, 2021 | Ophirex, Inc., Premier Research Group |
| NCT04969991 | Phase 2 | Jun 30, 2021 | Ophirex, Inc., Premier Research Group |
| NCT01522196 | Phase 2 | Feb 1, 2012 | Anthera Pharmaceuticals |
| NCT01359579 | Phase 1 | Jun 1, 2011 | Anthera Pharmaceuticals |
| NCT01359605 | Phase 1 | Jun 1, 2011 | Anthera Pharmaceuticals |
| NCT01130246 | Phase 3 | May 1, 2010 | Anthera Pharmaceuticals |
| NCT00743925 | Phase 2 | Jul 1, 2008 | Anthera Pharmaceuticals |
| NCT00533039 | Phase 2 | Oct 1, 2007 | Anthera Pharmaceuticals, University of Toronto |
| NCT00525954 | Phase 2 | Sep 1, 2007 | Anthera Pharmaceuticals |
| NCT00455546 | Phase 2 | Apr 1, 2007 | Anthera Pharmaceuticals |
| NCT00434473 | Phase 2 | Dec 1, 2006 | Anthera Pharmaceuticals |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anthera Pharmaceuticals | For profit | 9 | 8 | 3 | 2006 |
| Ophirex, Inc. | For profit | 3 | 3 | 1 | 2021 |
| Premier Research Group | For profit | 2 | 0 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2007 |
4 organizations
Page 1 / 1